| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | HHIP |
| Uniprot No | Q96QV1 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 18-700aa |
| 氨基酸序列 | FFE GDAKFGERNE GSGARRRRCL NGNPPKRLKR RDRRMMSQLE LLSGGEMLCG GFYPRLSCCL RSDSPGLGRL ENKIFSVTNN TECGKLLEEI KCALCSPHSQ SLFHSPEREV LERDLVLPLL CKDYCKEFFY TCRGHIPGFL QTTADEFCFY YARKDGGLCF PDFPRKQVRG PASNYLDQME EYDKVEEISR KHKHNCFCIQ EVVSGLRQPV GALHSGDGSQ RLFILEKEGY VKILTPEGEI FKEPYLDIHK LVQSGIKGGD ERGLLSLAFH PNYKKNGKLY VSYTTNQERW AIGPHDHILR VVEYTVSRKN PHQVDLRTAR VFLEVAELHR KHLGGQLLFG PDGFLYIILG DGMITLDDME EMDGLSDFTG SVLRLDVDTD MCNVPYSIPR SNPHFNSTNQ PPEVFAHGLH DPGRCAVDRH PTDININLTI LCSDSNGKNR SSARILQIIK GKDYESEPSL LEFKPFSNGP LVGGFVYRGC QSERLYGSYV FGDRNGNFLT LQQSPVTKQW QEKPLCLGTS GSCRGYFSGH ILGFGEDELG EVYILSSSKS MTQTHNGKLY KIVDPKRPLM PEECRATVQP AQTLTSECSR LCRNGYCTPT GKCCCSPGWE GDFCRTAKCE PACRHGGVCV RPNKCLCKKG YLGPQCEQVD RNIRRVTRAG ILDQIIDMTS YLLDLTSYIV |
| 预测分子量 | kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于HHIP重组蛋白的参考文献示例(注：以下文献为模拟示例，实际文献请通过学术数据库查询)：
---
1. **文献名称**: *Expression and Purification of Recombinant HHIP in Escherichia coli for Functional Studies*
**作者**: Y. Li et al.
**摘要**: 本研究报道了在大肠杆菌中高效表达和纯化HHIP重组蛋白的方法。通过优化诱导条件和亲和层析技术，获得了高纯度的HHIP蛋白，并验证了其与Hedgehog信号通路配体(如Shh)的结合活性。
2. **文献名称**: *Structural Insights into HHIP-Mediated Inhibition of Hedgehog Signaling*
**作者**: J. Smith et al.
**摘要**: 通过X射线晶体学解析了HHIP蛋白的三维结构，揭示了其与Hedgehog配体(如Shh和Ihh)相互作用的分子机制，为设计靶向Hedgehog通路的药物提供了结构基础。
3. **文献名称**: *HHIP Recombinant Protein Attenuates Lung Fibrosis in a Murine Model*
**作者**: R. Chen et al.
**摘要**: 利用重组HHIP蛋白在小鼠肺纤维化模型中验证其治疗潜力。实验表明，HHIP通过抑制Hedgehog信号通路，显著减少胶原沉积和炎症反应。
4. **文献名称**: *HHIP as a Biomarker in COPD: Recombinant Protein-Based Diagnostic Assay Development*
**作者**: K. Park et al.
**摘要**: 开发了一种基于重组HHIP蛋白的ELISA检测方法，用于评估慢性阻塞性肺病(COPD)患者血清中的HHIP水平，发现其与疾病严重程度呈负相关。
---
**注意**：以上文献为示例性内容，实际研究需通过PubMed、Web of Science或Google Scholar等平台检索关键词(如“HHIP recombinant protein”、“HHIP Hedgehog signaling”)获取。真实文献可能涉及HHIP在发育、癌症或肺部疾病中的功能研究。
The Hedgehog-interacting protein (HHIP) is a critical regulatory component of the Hedgehog (Hh) signaling pathway, a highly conserved developmental signaling cascade essential for embryogenesis, tissue patterning, and stem cell maintenance. Dysregulation of Hh signaling is implicated in various cancers, congenital disorders, and fibrotic diseases. HHIP acts as a membrane-associated or secreted glycoprotein that binds to all three mammalian Hh ligands (Sonic, Indian, and Desert Hedgehog), effectively sequestering them and preventing their interaction with the Patched (PTCH) receptor. This inhibitory function positions HHIP as a key endogenous modulator of Hh pathway activity, maintaining tissue homeostasis by fine-tuning ligand-dependent signaling.
Structurally, HHIP contains two distinct domains: an N-terminal domain rich in fibronectin type III repeats and a C-terminal domain with a globular structure. These features enable its high-affinity binding to Hh ligands. Recombinant HHIP proteins are engineered using expression systems like mammalian cells (e.g., HEK293) or insect cells to ensure proper post-translational modifications. These purified proteins retain the native ligand-binding capacity and are widely used as molecular tools to study Hh pathway mechanisms, screen for pathway inhibitors, or neutralize excessive Hh signaling in experimental models.
In therapeutic contexts, recombinant HHIP has shown promise in preclinical studies for conditions driven by aberrant Hh activation, including basal cell carcinoma, pancreatic cancer, and pulmonary fibrosis. Its potential as a biologic therapeutic stems from its ability to directly counteract ligand-dependent pathway overactivation while avoiding off-target effects associated with small-molecule inhibitors. Additionally, HHIP serves as a biomarker in clinical research, as its expression levels often inversely correlate with Hh pathway activity in diseased tissues. Ongoing research continues to explore its structural optimization, delivery strategies, and combinatorial approaches with other pathway modulators.
×
